The 75 references in paper V. Trofimov I., L. Sorokina N., В. Трофимов И., Л. Сорокина Н. (2014) “ПАТОГЕНЕТИЧЕСКИЕ ОСНОВЫ ХОЛИНОЛИТИЧЕСКОЙ ТЕРАПИИ И ВОЗМОЖНЫЕ МЕХАНИЗМЫ ЕЕ ПОТЕНЦИРОВАНИЯ ПОД ВЛИЯНИЕМ β2-АДРЕНОМИМЕТИКОВ // MECHANISMS OF ANTICHOLINERGIC EFFECTS AND PROBABLE MECHANISMS OF THEIR POTENTIATION USING BETA-2-AGONISTS” / spz:neicon:pulmonology:y:2014:i:2:p:91-99

1
Gosens R., Zaagsma J., Meurs H., Halayko A. J. Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir. Res. 2006; 7: article 73.
(check this in PDF content)
2
Kistemaker L. E., Oenema T. A., Meurs H., Gosens R. Regulation of airway inflammation and remodeling by muscarinic receptors: perspectives on anticholinergic therapy in asthma and COPD. Life Sci. 2012; 91 (21–22): 1126–1133.
(check this in PDF content)
3
Gosens R., Bos I.S., Zaagsma J., Meurs H. Protective effects of tiotropium bromide in the progression of airway smooth muscle remodeling. Am. J. Respir. Crit. Care Med. 2005; 171: 1096–1102.
(check this in PDF content)
4
Caulfield M.P., Birdsall N.J.M. International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 1998; 50 (2): 279–290.
(check this in PDF content)
5
Wessler I.K., Kirkpatrick C.J. The non-neuronal cholinergic system: an emerging drug target in the airways. Pulm. Pharmacol. Ther. 2001; 14 (6): 423–434.
(check this in PDF content)
6
Mak J.C., Barnes P.J. Autoradiographic visualization of muscarinic receptor subtypes in human and guinea pig lung. Am. Rev. Respir. Dis. 1990; 141 (1): 1559–1568.
(check this in PDF content)
7
Ramnarine S.I., Haddad E.B., Khawaja A.M. et al.On muscarinic control of neurogenic mucus secretion in ferret trachea. J. Physiol. (Lond.). 1996; 494: 577–586.
(check this in PDF content)
8
Ishihara H., Shimura S., Satoh M. et al. Muscarinic receptor subtypes in feline tracheal submucosal gland secretion. Am. J. Physiol. 1992; 262: 223–228.
(check this in PDF content)
9
Roffel A.F., Elzinga C.R., Van Amsterdam R.G. et al. Muscarinic M2 receptors in bovine tracheal smooth muscle: discrepancies between binding and function. Eur. J. Pharmacol. 1988; 153: 73–82.
(check this in PDF content)
10
Patel H.J., Barnes P.J., Takahashi T. et al.Evidence for prejunctional muscarinic autoreceptors in human and guinea pig trachea. Am. J. Respir. Crit. Care Med. 1995; 152 (3): 872–878.
(check this in PDF content)
11
ten Berge R.E.J., Zaagsma J., Roffel A.F. Muscarinic inhibitory autoreceptors in different generations of human airways. Am. J. Respir. Crit. Care Med. 1996; 154 (1): 43–49.
(check this in PDF content)
12
Nieuwstadt R.A., Henricks P.A., Hajer R. et al.Characterization of muscarinic receptors in equine tracheal smooth muscle in vitro. Vet. Quart. 1997; 19 (2): 54–57.
(check this in PDF content)
13
Fisher J.T., Vincent S.G., Gomeza J. et al.Loss of vagally mediated bradycardia and bronchoconstriction in mice lacking M2 or M3 muscarinic acetylcholine receptors. FASEB J. 2004; 18 (6): 711–713.
(check this in PDF content)
14
Minette P.A., Lammers J.W., Dixon C.M. et al. A muscarinic agonist inhibits reflex bronchoconstriction in normal but not in asthmatic subjects. J. Appl. Physiol. 1989; 67 (6): 2461–2465.
(check this in PDF content)
15
Felder C.C. Muscarinic acetylcholine receptors: signal transduction through multiple effectors. FASEB J. 1995; 9 (8): 619–625.
(check this in PDF content)
16
Higashida H., Yokoyama S., Hashii M. et al. Muscarinic receptor-mediated dual regulation of ADP-ribosyl cyclase in NG108-15 neuronal cell membranes. J. Biol. Chem. 1997; 272 (50): 31272–31277.
(check this in PDF content)
17
White T.A., Kannan M.S., Walseth T.F. Intracellular calcium signaling through the cADPR pathway is agonist specific in porcine airway smooth muscle. FASEB J. 2003; 17 (3): 482–484.
(check this in PDF content)
18
Tliba O., Cidlowski J., Amrani Y. CD38 expression is insensitive to steroid action in cells treated with TNF-αand IFN-γby a mechanism involving the upregulation of glucocorticoid receptor βisoform. Mol. Pharmacol. 2006; 69 (2): 588–596.
(check this in PDF content)
19
Deshpande D.A., Walseth T.F., Panettieri R.A., Kannan M.S. CD38/cyclic ADP-ribose-mediated Ca2+signaling contributes to airway smooth muscle hyper-responsiveness. FASEB J. 2003; 17 (3): 452–454.
(check this in PDF content)
20
Deshpande D.A., Dogan S., Walseth T.F. et al. Modulation of calcium signaling by interleukin-13 in human airway smooth muscle: role of CD38/cyclic adenosine diphosphate ribose pathway. Am. J. Respir. Cell Mol. Biol. 2004; 31 (1): 36–42.
(check this in PDF content)
21
Tliba O., Panettieri R.A. Jr, Tliba S. et al. Tumor necrosis factor-alpha differentially regulates the expression of proinflammatory genes in human airway smooth muscle cells by activation of interferon-beta-dependent CD38 pathway. Mol. Pharmacol. 2004; 66 (2): 322–329.
(check this in PDF content)
22
Hirshman C.A., Lande B., Croxton T.L. Role of M2 muscarinic receptors in airway smooth muscle contraction. Life Sci. 1999; 64: 443–448.
(check this in PDF content)
23
Yoshii A., Iizuka K., Dobashi K. et al. Relaxation of contracted rabbit tracheal and human bronchial smooth muscle by Y-27632 through inhibition of Ca2+sensitization. Am. J. Respir. Cell Mol. Biol. 1999; 20 (6): 1190–1200.
(check this in PDF content)
24
Janssen L.J., Wattie J., Lu-Chao H., Tazzeo T. Muscarinic excitationcontraction coupling mechanisms in tracheal and bronchial smooth muscles. J. Appl. Physiol. 2001; 91 (3): 1142–1151.
(check this in PDF content)
25
Schaafsma D., Gosens R., Bos I.S. et al. Allergic sensitization enhances the contribution of Rho-kinase to airway smooth muscle contraction. Br. J. Pharmacol. 2004; 143 (4): 477–484.
(check this in PDF content)
26
Chiba Y., Ueno A., Shinozaki K. et al.Involvement of RhoAmediated Ca2+sensitization in antigen-induced bronchial smooth muscle hyperresponsiveness in mice. Respir. Res. 2005; 6: 4.
(check this in PDF content)
27
Chiba Y., Sakai H., Misawa M.Augmented acetylcholineinduced translocation of RhoA in bronchial smooth muscle from antigen-induced airway hyperresponsive rats. Br. J. Pharmacol. 2001; 133 (6): 886–890.
(check this in PDF content)
28
Chiba Y., Murata M., Ushikubo H. et al.Effect of cigarette smoke exposure in vivo on bronchial smooth muscle contractility in vitro in rats. Am. J. Respir. Cell Mol. Biol. 2005; 33 (6): 574–581.
(check this in PDF content)
29
ten Berge R.E., Santing R.E., Hamstra J.J. et al. Dysfunction of muscarinic M2 receptors after the early allergic reaction: possible contribution to bronchial hyperresponsiveness in allergic guinea-pigs. Br. J. Pharmacol. 1995; 114 (4): 881–887.
(check this in PDF content)
30
Coulson F.R., Fryer A.D. Muscarinic acetylcholine receptors and airway diseases. Pharmacol. Ther. 2003; 98 (1): 59–69.
(check this in PDF content)
31
Yang Z.J., Biggs D.F. Muscarinic receptors and parasympathetic neurotransmission in guinea-pig trachea. Eur. J. Pharmacol. 1991; 193 (3): 301–308.
(check this in PDF content)
32
On L.S., Boonyongsunchai P., Webb S. et al. Function of pulmonary neuronal M(2) muscarinic receptors in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163 (6): 1320–1325.
(check this in PDF content)
33
Belmonte K.E.Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005; 2 (4): 297–304; discuss.: 311–312.
(check this in PDF content)
34
Tashkin D.P., Fabbri L.M.Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir. Res. 2010; 11 (1): 149.
(check this in PDF content)
35
Undem B.J., Kollarik M. The role of vagal afferent nerves in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2005: 2 (4): 355-360; discuss. 371–372.
(check this in PDF content)
36
Spina D., Shah S., Harrison S.Modulation of sensory nerve function in the airways. Trends Pharmacol. Sci. 1998; 19 (11): 460–466.
(check this in PDF content)
37
Selivanova P.A., Kulikov E.S., Kozina O.V. et al. Differential expression of the β2-adrenoreceptor and M3-cholinoreceptor genes in bronchial mucosa of patients with asthma and chronic obstructive pulmonary disease. Ann. Allergy Asthma Immunol. 2012; 108 (1): 39–43.
(check this in PDF content)
38
Selivanova P.A., Kulikov E.S., Kozina O.V. et al.Morphological and molecular characteristics of "difficult" asthma. J. Asthma. 2010; 47 (3): 269–275.
(check this in PDF content)
39
Rogers D.F. Muscarinic control of airway mucus secretion. In: Zaagsma J., Meurs H., Roffel A.F., eds. Muscarinic Receptors in Airways Diseases. Basel; 2001: 175–201.
(check this in PDF content)
40
Rogers D.F. Airway mucus hypersecretion in asthma: an undervalued pathology? Curr. Opin. Pharmacol. 2004; 4 (3): 241–250.
(check this in PDF content)
41
Amishima M., Munakata M., Nasuhara Y. et al.Expression of epidermal growth factor and epidermal growth factor receptor immunoreactivity in the asthmatic human airway. Am. J. Respir. Crit. Care Med. 1998; 157 (6): 1907–1912.
(check this in PDF content)
42
Wessler I., Reinheimer T., Kilbinger H. et al. Increased acetylcholine levels in skin biopsies of patients with atopic dermatitis. Life Sci. 2003; 72 (18–19): 2169–2172.
(check this in PDF content)
43
Strom T.B., Deisseroth A., Morganroth J. et al. Alteration of the cytotoxic action of sensitized lymphocytes by cholinergic agents and activators of adenylate cyclase. Proc. Natl Acad. Sci. USA. 1972; 69 (10): 2995–2999.
(check this in PDF content)
44
Profita M., Giorgi R.D., Sala A. et al.Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy. 2005; 60 (11): 1361–1369.
(check this in PDF content)
45
Bai T.R., Cooper J., Koelmeyer T. et al. The effect of age and duration of disease on airway structure in fatal asthma. Am. J. Respir. Crit. Care Med. 2000; 162 (2): 663–669.
(check this in PDF content)
46
Gosens R., Zaagsma J., Grootte Bromhaar M. et al. Acetylcholine: a novel regulator of airway smooth muscle remodelling? Eur. J. Pharmacol. 2004; 500: 193–201.
(check this in PDF content)
47
Grainge C.L., Lau L.C., Ward J.A. et al.Effect of bronchoconstriction on airway remodeling in asthma. N. Engl. J. Med. 2011; 364 (21): 2006–2015.
(check this in PDF content)
48
Matthiesen S., Kempkens S., Bahulayan A. et al. Muscarinic receptors mediate stimulation of human lung fibroblast proliferation. Am. J. Respir. Cell Mol. Biol. 2006; 35 (6): 621–627.
(check this in PDF content)
49
Krymskaya V.P., Orsini M.J., Eszterhas A.J. et al. Mechanisms of proliferation synergy by receptor tyrosine kinase and G protein-coupled receptor activation in human airway smooth muscle. Am. J. Respir. Cell Mol. Biol. 2000; 23 (4): 546–554.
(check this in PDF content)
50
Petrie G.R., Palmer K.N.V. Comparison of aerosol ipratropium bromide and salbutamol in chronic bronchitis and asthma. Br. Med. J. 1975; 1 (5955): 430–432.
(check this in PDF content)
51
Anthonisen N.R., Connett J.E., Kiley J.P. et al.Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. J.A.M.A. 1994; 272 (19): 1497–1505.
(check this in PDF content)
52
Anzueto A., Tashkin D., Menjoge S., Kesten S. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm. Pharmacol. Ther. 2005; 18: 75–81.
(check this in PDF content)
53
Zhang W.H., Zhang Y., Cui Y.Y. et al. Can beta-2-adrenoceptor agonists, anticholinergic drugs, and theophylline contribute to the control of pulmonary inflammation and emphysema in COPD? Fundam. Clin. Pharmacol. 2012; 26 (1): 118–134.
(check this in PDF content)
54
Cazzola M., Molimard M. The scientific rationale for combining long-acting beta-2-agonists and muscarinic antagonists in COPD. Pulm. Pharmacol. Ther. 2010; 23 (4): 257–267.
(check this in PDF content)
55
Dorinsky P.M., Reisner C., Ferguson G.T. et al.The combination of ipratropium and albuterol optimizes pulmonary function reversibility test in patients with COPD. Chest 1999; 115 (4): 966–971.
(check this in PDF content)
56
Easton P.A., Jadue C., Dhingra S., Anthonisen N.R.A comparison of the bronchodilating effects of a beta-2-adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence. N. Engl. J. Med. 1986; 315 (12): 735–739.
(check this in PDF content)
57
LeDoux E.J., Morris J.F., Temple W.P., Duncan C. Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled meta-proterenol in COPD. Chest 1989; 95 (5): 1013–1016.
(check this in PDF content)
58
COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratТрофимов В.И., Сорокина Л.Н.Патогенетические основы холинолитической терапии и механизмы ее потенцирования ropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994; 105 (5): 1411–1419.
(check this in PDF content)
59
Levin D.C., Little K.S., Laughlin K.R. et al. Addition of anticholinergic solution prolongs bronchodilator effect of beta2 agonists in patients with chronic obstructive pulmonary disease. Am. J. Med. 1996; 100: 40S–48S.
(check this in PDF content)
60
COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest. 1997: 112: 1514–1521.
(check this in PDF content)
61
Sarria B., Naline E., Zhang Y. et al. Muscarinic M2 receptors in acetylcholine-isoproterenol functional antagonism in human isolated bronchus. Am. J. Physiol. Lung Cell Mol. Physiol. 2002; 283 (5): 1125–1132.
(check this in PDF content)
62
Canning B.J., Fischer A. Neural regulation of airway smooth muscle tone. Respir. Physiol. 2001; 125: 113–127.
(check this in PDF content)
63
Postma D.S., Keyzer J.J., Koeter G.H. et al.Influence of the parasympathetic and sympathetic nervous system on nocturnal bronchial obstruction. Clin. Sci. 1985; 69: 251–258.
(check this in PDF content)
64
Gaultier C., Reinberg A., Girard E.Circadian rhythms in lung resistance and dynamic lung compliance of healthy children. Effects of two bronchodilators. Respir. Physiol. 1977; 31 (2): 169–182.
(check this in PDF content)
65
Furlan R., Guzzetti S., Crivellaro W. et al.Continuous 24hour assessment of the neural regulation of systemic arterial pressure and RR variabilities in ambulant subjects. Circulation 1990; 81 (2): 537–547.
(check this in PDF content)
66
Daniel E.E., Kannan M., Davis C., Posey-Daniel V. Ultrastructural studies on the neuromuscular control of human tracheal and bronchial muscle. Respir. Physiol. 1986; 63: 109–128.
(check this in PDF content)
67
Rhoden K.J., Meldrum L.A., Barnes P.J.Inhibition of cholinergic neurotransmission in human airways by β2-adrenoceptors. J. Appl. Physiol. 1988; 65: 700–705.
(check this in PDF content)
68
Aizawa H., Inoue H., Ikeda T. et al. Effects of procaterol, aβ2-adrenoceptor stimulant, on neuroeffector transmission in human bronchial tissue. Respiration. 1991; 58: 163–166.
(check this in PDF content)
69
Zhang X.Y., Olszewski M.A., Robinson N.E.β2-Adrenoceptor activation augments acetylcholine release from tracheal parasympathetic nerves. Am. J. Physiol. 1995; 268: 950–956.
(check this in PDF content)
70
Kume H., Graziano M.P., Kotlikoff M.I.Stimulatory and inhibitory regulation of calcium-activated potassium channels by guanine nucleotide-binding proteins. Proc. Natl Acad. Sci. 1992; 89 (22): 11051–11055.
(check this in PDF content)
71
Patel H.J., Giembycz M.A., Keeling J.E. et al. Inhibition of cholinergic neurotransmission in guinea pig trachea by NS1619, a putative activator of large-conductance, calcium-activated potassium channels. J. Pharmacol. Exp. Ther. 1998; 286: 952–958.
(check this in PDF content)
72
Wedzicha Y.A., Decramer M., Ficker J.H. et al.Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK):a randomised, doubleblind, parallel-group study. Lancet Respir. Med. 2013; 1 (3): 199–209.
(check this in PDF content)
73
Bateman E.D., Ferguson G.T., Barnes N. et al.Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur. Respir. J. 2013; 42 (6): 1484–1494.
(check this in PDF content)
74
Vogelmeier C.F., Bateman E.D., Pallante J. et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir. Med. 2013; 1 (1): 51–60.
(check this in PDF content)
75
Dahl R., Jadayel D., Alagappan V.K. et al. Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponentsindacaterol and glycopyrronium: the BEACON study. Int. J. COPD. 2013; 8: 501–508. Информация об авторах
(check this in PDF content)